Fulcrum Therapeutics, Inc. (FULC) Research

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
FULC
Price
$3.70
Day change
+5.71%
Market cap
$200.2M
P/E ratio
-3.70x
52-week range
2.83-15.74
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$3.60

Recent news

  • What's Going On With Fulcrum Therapeutics Stock On Thursday?

    Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cell disease.

  • Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

    Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk ​concerns raised by the U.S. FDA, and explore strategic options ‌including a potential sale or merger.

  • FULC Stock Crashes After Hours: What Investors Need To Know

    Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.

Peer companies

  • ADC Therapeutics S.A. (ADCT)
  • Bicycle Therapeutics plc (BCYC)
  • Compass Therapeutics, Inc. (CMPX)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Lexicon Pharmaceuticals, Inc. (LXRX)
  • Neurogene Inc. (NGNE)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Ocugen, Inc. (OCGN)

Recent insider activity

  • Lehrer-Graiwer Joshua — A-Award (64000 shares) on 2026-04-23
  • Lehrer-Graiwer Joshua — trade (0 shares) on 2026-04-23
  • Gould Robert J — S-Sale (15000 shares) on 2026-01-02
  • Musso Alan A — A-Award (170000 shares) on 2026-02-02
  • Oltmans Curtis Gale — A-Award (170000 shares) on 2026-02-02

Open Fulcrum Therapeutics, Inc. (FULC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.